StockNews.AI
CALC
StockNews.AI
68 days

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

1. CalciMedica announces upcoming symposium on Auxora for AKI treatment. 2. Presentations to highlight CRAC channels and its role in AKI. 3. Auxora has shown positive results in multiple clinical trials. 4. CalciMedica focused on inflammatory and immunologic diseases. 5. Webcasts of the presentations to be available online.

5m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical results and a significant symposium raise investor interest. Similar companies often see price increases post-symposia that highlight breakthroughs.

How important is it?

The article discusses a critical event for CALC that may enhance visibility and credibility among investors.

Why Short Term?

The upcoming symposium and its immediate results can influence short-term investor sentiment. Quick gains in stock price often follow positive exposure at such events.

Related Companies

NDAQ: CRMDNDAQ: ABUSNDAQ: CERE
, /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced an upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy. Details for the oral presentations to be presented during the symposium are as follows: Presentation Title: Overview of Calcium Release-Activated Calcium (CRAC) ChannelsPresenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedicaDate and Time: Tuesday, June 24, 1:45-2:00 p.m. CEST Presentation Title: The Role of IL-17 in the Pathophysiology of AKIPresenter: Javier Neyra, M.D., Associate Professor of Medicine and Associate Director of the Nephrology Research & Training Center at University of Alabama at BirminghamDate and Time: Tuesday, June 24, 2:00-2:20 p.m. CEST Presentation Title: KOURAGE (NCT06374797)Presenter: Lakhmir Chawla, M.D., Clinical Professor of Medicine at University of California San Diego, Chief Medical Officer at ExThera Medical, and Chair of the KOURAGE Steering CommitteeDate and Time: Tuesday, June 24, 2:20-2:35 p.m. CEST Webcasts of the presentations will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at https://ir.calcimedica.com/news-events/medical-events-publications. About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visit www.calcimedica.com. Contact InformationArgot Partners[email protected](212) 600-1902 SOURCE CalciMedica, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News